Management of Ocular Infections and Conjunctivitis

Initial Differentiation and Treatment Strategy

The American Academy of Ophthalmology recommends prescribing a 5-7 day course of topical broad-spectrum antibiotics for bacterial conjunctivitis, as this accelerates clinical resolution, reduces transmissibility, and allows earlier return to work or school, even in mild cases 1, 2
The World Health Organization-endorsed options for mild bacterial conjunctivitis include topical gentamicin, tetracycline, or ofloxacin, with a strength of evidence based on clinical guidelines 4, 2

The American Academy of Ophthalmology suggests choosing topical fluoroquinolones, such as moxifloxacin 0.5% or ofloxacin, as first-line therapy for bacterial conjunctivitis, administered 3-4 times daily for 5-7 days, with moderate to high strength of evidence 2, 3
For moderate to severe bacterial conjunctivitis, fluoroquinolones are recommended, with a high strength of evidence based on clinical trials 2

The Centers for Disease Control and Prevention recommend immediate systemic antibiotic therapy, plus topical treatment and saline lavage, for gonococcal conjunctivitis, which is a hyperacute, vision-threatening emergency, with high strength of evidence 1, 2
The American Academy of Pediatrics recommends ceftriaxone 250 mg IM single dose for adults and 125 mg IM single dose for children <45 kg with gonococcal conjunctivitis, with high strength of evidence 5
The World Health Organization recommends single-dose oral azithromycin or 1 week of oral tetracycline for adults with chlamydial conjunctivitis, with moderate strength of evidence 4, 2

The American Academy of Ophthalmology recommends no antibiotics for viral conjunctivitis, focusing on patient education about contagion control and symptomatic relief, with high strength of evidence 1, 6
The American Academy of Ophthalmology suggests educating patients about a 10-14 day contagious period from onset and instructing on frequent handwashing, separate towels/pillows, and avoiding close contact, with moderate strength of evidence 1, 3

The American Academy of Ophthalmology recommends treating allergic conjunctivitis with topical antihistamines and mast cell stabilizers, reserving corticosteroids for severe vernal conjunctivitis exacerbations, with moderate strength of evidence 1

The American Academy of Ophthalmology advises patients to return if no improvement after 3-4 days of treatment, with moderate strength of evidence 2, 3, 5
The American Academy of Ophthalmology recommends referring immediately to an ophthalmologist for visual loss, moderate or severe pain, severe purulent discharge, corneal involvement, conjunctival scarring, lack of response to therapy, or recurrent episodes, with high strength of evidence 2, 5

The American Academy of Ophthalmology warns about the increasing isolation of MRSA, which is resistant to many commercially available topical antibiotics, and may require compounded topical vancomycin, with high strength of evidence 2, 3
The World Health Organization notes that Pseudomonas aeruginosa resistance to moxifloxacin increased from 19% to 52% in southern India (2007-2009), with moderate strength of evidence 3